美国门诊苯二氮䓬类处方模式
该系列横断面研究利用2003年1月1日至2015年12月31日全国门诊医疗调查数据,分析成人门诊苯二氮䓬类处方模式。苯二氮䓬类就诊率从3.8%升至7.4%(P<.001),初级保健医生约占半数(52.3%)。与阿片类共处方率从0.5%升至2.0%(P<.001),与其他镇静药物共处方率从0.7%升至1.5%(P<.001)。作者认为,理解并干预处方模式可能有助于遏制苯二氮䓬类使用增长。
要点
- 门诊苯二氮䓬类就诊率从2003年3.8%(95%CI 3.2%-4.4%)翻倍至2015年7.4%(95%CI 6.4%-8.6%),P<.001。
- 初级保健医生占所有苯二氮䓬类就诊约一半(52.3%,95%CI 50.0%-54.6%)。
- 苯二氮䓬类与阿片类共处方率从2003年0.5%(95%CI 0.3%-0.7%)增至2015年2.0%(95%CI 1.4%-2.7%),P<.001。
- 苯二氮䓬类与其他镇静药物共处方率从0.7%(95%CI 0.5%-0.9%)增至1.5%(95%CI 1.1%-1.9%),P<.001。
- 背部和/或慢性疼痛就诊中苯二氮䓬类使用率从3.6%(95%CI 2.6%-4.9%)升至8.5%(95%CI 6.0%-11.9%),P<.001。
适用人群与场景
- 2003年至2015年美国成人门诊就诊(全国代表性样本,每年约2万至2.4万次就诊,代表7.37亿至8.41亿次就诊)。
研究设计与关键结果
- 研究类型:系列横断面研究,使用2003年1月1日至2015年12月31日全国门诊医疗调查数据,分析386457次门诊就诊,其中2003年919次苯二氮䓬类就诊(全国代表2760万次),2015年1672次(全国代表6260万次)。
- 主要终点:苯二氮䓬类就诊率从2003年3.8%(95%CI 3.2%-4.4%)升至2015年7.4%(95%CI 6.4%-8.6%),P<.001。
- 专科分布:初级保健医生占所有苯二氮䓬类就诊52.3%(95%CI 50.0%-54.6%);精神科医生就诊中苯二氮䓬类使用率2003年29.6%(95%CI 23.3%-36.7%) vs 2015年30.2%(95%CI 25.6%-35.2%),P=.90;初级保健医生就诊中使用率从3.6%(95%CI 2.9%-4.4%)升至7.5%(95%CI 6.0%-9.5%),P<.001。
- 适应症:焦虑和抑郁就诊中使用率从26.6%(95%CI 22.6%-31.0%)升至33.5%(95%CI 28.8%-38.6%),P=.003;神经系统疾病从6.8%(95%CI 4.8%-9.5%)升至8.7%(95%CI 6.2%-12.1%),P<.001;背部和/或慢性疼痛从3.6%(95%CI 2.6%-4.9%)升至8.5%(95%CI 6.0%-11.9%),P<.001;其他疾病从1.8%(95%CI 1.4%-2.2%)升至4.4%(95%CI 3.7%-5.2%),P<.001;失眠无显著变化:26.9%(95%CI 19.3%-36.0%) vs 25.6%(95%CI 15.3%-39.6%),P=.72。
- 共处方:与阿片类共处方率从2003年0.5%(95%CI 0.3%-0.7%)升至2015年2.0%(95%CI 1.4%-2.7%),P<.001;与其他镇静药物共处方率从0.7%(95%CI 0.5%-0.9%)升至1.5%(95%CI 1.1%-1.9%),P<.001。
证据类型、等级与局限
- 证据类型:系列横断面研究,使用全国代表性调查数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。作者认为,鉴于苯二氮䓬类相关过量死亡增加,理解并干预处方模式可能有助于遏制苯二氮䓬类使用增长。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Benzodiazepines are implicated in a growing number of overdose-related deaths.
OBJECTIVES: To quantify patterns in outpatient benzodiazepine prescribing and to compare them across specialties and indications.
DESIGN, SETTING, AND PARTICIPANTS: This serial cross-sectional study (January 1, 2003, through December 31, 2015) used nationally representative National Ambulatory Medical Care Survey data. The yearly population-based sample of outpatient visits among adults, ranging from 20 884 visits in 2003 (representing 737 million visits) to 24 273 visits in 2015 (representing 841 million visits) was analyzed. Prescribing patterns were examined by specialty and indication and used to calculate the annual coprescribing rate of benzodiazepines with other sedating medications. Data were analyzed from July 1, 2017, through November 30, 2018.
MAIN OUTCOMES AND MEASURES: Annual benzodiazepine visit rate.
RESULTS: Among the 386 457 ambulatory care visits from 2003 through 2015, a total of 919 benzodiazepine visits occurred in 2003 and 1672 in 2015, nationally representing 27.6 million and 62.6 million visits, respectively. The benzodiazepine visit rate doubled from 3.8% (95% CI, 3.2%-4.4%) to 7.4% (95% CI, 6.4%-8.6%; P < .001) of visits. Visits to primary care physicians accounted for approximately half of all benzodiazepine visits (52.3% [95% CI, 50.0%-54.6%]). The benzodiazepine visit rate did not change among visits to psychiatrists (29.6% [95% CI, 23.3%-36.7%] in 2003 to 30.2% [95% CI, 25.6%-35.2%] in 2015; P = .90), but increased among all other physicians, including primary care physicians (3.6% [95% CI, 2.9%-4.4%] to 7.5% [95% CI, 6.0%-9.5%]; P < .001). The benzodiazepine visit rate increased slightly for anxiety and depression (26.6% [95% CI, 22.6%-31.0%] to 33.5% [95% CI, 28.8%-38.6%]; P = .003) and neurologic conditions (6.8% [95% CI, 4.8%-9.5%] to 8.7% [95% CI, 6.2%-12.1%]; P < .001), but more so for back and/or chronic pain (3.6% [95% CI, 2.6%-4.9%] to 8.5% [95% CI, 6.0%-11.9%]; P < .001) and other conditions (1.8% [95% CI, 1.4%-2.2%] to 4.4% [95% CI, 3.7%-5.2%]; P < .001); use did not change for insomnia (26.9% [95% CI, 19.3%-36.0%] to 25.6% [95% CI, 15.3%-39.6%]; P = .72). The coprescribing rate of benzodiazepines with opioids quadrupled from 0.5% (95% CI, 0.3%-0.7%) in 2003 to 2.0% (95% CI, 1.4%-2.7%) in 2015 (P < .001); the coprescribing rate with other sedating medications doubled from 0.7% (95% CI, 0.5%-0.9%) to 1.5% (95% CI, 1.1%-1.9%) (P < .001).
CONCLUSIONS AND RELEVANCE: The outpatient use of benzodiazepines has increased substantially. In light of increasing rates of overdose deaths involving benzodiazepines, understanding and addressing prescribing patterns may help curb the growing use of benzodiazepines.
参考来源
- Agarwal SD, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Netw Open. 2019. PMID: 30681713. doi:10.1001/jamanetworkopen.2018.7399
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。